Metabolic plasticity in CLL: Adaptation to the hypoxic niche

Leukemia

Volumn 30, Issue 1, 2016, Pages 65-73

  Koczula, K M ^a   Ludwig, C ^a   Hayden, R ^a   Cronin, L ^a   Pratt, G ^a,b   Parry, H ^a   Tennant, D ^a   Drayson, M ^a   Bunce, C M ^a   Khanim, F L ^a   Gunther, U L ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HIF1A PROTEIN, HUMAN; PYRUVIC ACID;

ARTICLE; CANCER CELL; CELL KILLING; CELL METABOLISM; CELL PLASTICITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPOXIA; MAJOR CLINICAL STUDY; METABOLIC PLASTICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR OVERHAUSER EFFECT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ADAPTATION; CELL CYCLE CHECKPOINT; CELL HYPOXIA; CITRIC ACID CYCLE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ADAPTATION, PHYSIOLOGICAL; CELL CYCLE CHECKPOINTS; CELL HYPOXIA; CITRIC ACID CYCLE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MAGNETIC RESONANCE SPECTROSCOPY; PYRUVIC ACID;

EID: 84953352481     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.187     Document Type: Article

References (23)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
2. D'Arena G, Di Renzo N, Brugiatelli M, Vigliotti ML, Keating MJ. Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemia. Leukemia & lymphoma 2003; 44: 223-228.
3. Parker TL, Strout MP. Chronic lymphocytic leukemia: prognostic factors and impact on treatment. Discov Med 2011; 11: 115-123.
4. Hayden RE, Pratt G, Roberts C, Drayson MT, Bunce CM. Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches. Leukemia & lymphoma 2012; 53: 537-549.
5. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755-764.
6. Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011; 2011: 96-103.
7. Jones NP, Schulze A. Targeting cancer metabolism-aiming at a tumour's sweet-spot. Drug Discov Today 2012; 17: 232-241.
8. Armitage E, Barbas C. Metabolomics in cancer biomarker discovery: Current trends and future perspectives. J Pharm Biomed Anal 2014; 87: 11-11.
9. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011; 11: 325-337.
10. Ward PS, Thompson CB. Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate. Cancer Cell 2012; 21: 297-308.
11. Gunther UL, Ludwig C, Ruterjans H. NMRLAB-Advanced NMR data processing in matlab. J Magn Reson 2000; 145: 201-208.
12. Ludwig C, Gunther UL. MetaboLab-advanced NMR data processing and analysis for metabolomics. BMC bioinformatics 2011; 12: 366.
13. Cohen JS, Motiei M, Carmi S, Shiperto D, Yefet O, Ringel I. Determination of intracellular pH and compartmentation using diffusion-weighted NMR spectroscopy with pH-sensitive indicators. Magn Reson Med 2004; 51: 900-903.
14. Ghosh AK, Shanafelt TD, Cimmino A, Taccioli C, Volinia S, Liu CG et al. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood 2009; 113: 5568-5574.
15. Cook KM, Hilton ST, Mecinovic J, Motherwell WB, Figg WD, Schofield CJ. Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J Biol Chem 2009; 284: 26831-26838.
16. Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U et al. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci USA 2008; 105: 19643-19648.
17. Huang CY, Kuo WT, Huang YC, Lee TC, Yu LC. Resistance to hypoxia-induced necroptosis is conferred by glycolytic pyruvate scavenging of mitochondrial superoxide in colorectal cancer cells. Cell Death Dis 2013; 4: e622.
18. Cipolleschi MG, Marzi I, Santini R, Fredducci D, Vinci MC, D'Amico M et al. Hypoxiaresistant profile implies vulnerability of cancer stem cells to physiological agents, which suggests new therapeutic targets. Cell Cycle 2014; 13: 268-278.
19. Smith M. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359-7368.
20. Chiorazzi N. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 2007; 20: 399-413.
21. Lemons JM, Feng XJ, Bennett BD, Legesse-Miller A, Johnson EL, Raitman I et al. Quiescent fibroblasts exhibit high metabolic activity. PLoS Biol 2010; 8: e1000514.
22. Yang C, Harrison C, Jin ES, Chuang DT, Sherry AD, Malloy CR et al. Simultaneous steady-state and dynamic 13C NMR can differentiate alternative routes of pyruvate metabolism in living cancer cells. J Biol Chem 2014; 289: 6212-6224.
23. Harris T, Degani H, Frydman L. Hyperpolarized 13C NMR studies of glucose metabolism in living breast cancer cell cultures. NMR Biomedicine 2013; 26: 1831-1843.